Lodenosine, 6-Amino-9-(2,3-dideoxy-2-fluoro-beta-D-threo- pentofuranosyl)-9H-purine, an antiretroviral agent discovered and developed in this laboratory is currently in Phase I/II clinical trials (www.aegis.com/pub/beta/1998/BE981003.html) for the treatment of AIDS. The LMC is currently interested in developing new, alternative synthesis of lodenosine to improve efficiency and lower the cost of the drug. The new approach reported last year, which consisted in the reduction of the corresponding methyl xanthate of 6-methoxy-9-(2-deoxy- 2-fluoro-5-benzoyl beta-D-arabinofuranosyl)-9H-purine to beta-F-ddA, was further improved by using isopropanol as solvent and reducing agent instead of diglyme. The new radical reduction is very efficient, avoids the use of the expensive and flammable tributyltin hydride, and produces lodenosine in high yield after ammonolysis of the 6-methoxy group. At the mechanistic level, a conformational study where the triphosphate of lodenosine and its corresponding 2?-anomer (alpha-FddA) were docked at the active site of the ternary complex of HIV-1 RT-DNA- dNTP (by replacing the dNTP with either triphosphate analogue) strongly suggests that the alpha-FddATP, despite having a favorable A- conformation (North sugar pucker), is less effective than beta-FddATP due to a strong steric clash between the fluorine atom and Tyrosine 115. Tyrosine 115 is a highly conserved amino acid that functions as a gate keeper in HIV-1 RT to prevent the incorporation of ribonucleotides. Indeed the measured IC50 for inhibiting HIV-1 RT demonstrated that there is a 4-fold difference in potency favoring the beta-FddATP. Pro-drug delivery of beta-F-ddA continues to be an important avenue of research to by-pass adenosine deamination. Preliminary information indicates that the pro-drug approach is highly beneficial in improving the potency of lodenosine.AIDS title: Fluorodideoxynucleosides as Reverse Transcriptase Inhibitors for the Treatment of AIDS. - AIDS, dideoxynucleosides, fluoronucleosides, HIV, Reverse Transcriptase,

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC006173-14
Application #
6289175
Study Section
Special Emphasis Panel (LMC)
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
1999
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Russ, Pamela L; Gonzalez-Moa, Maria J; Vu, B Christie et al. (2009) North- and south-bicyclo[3.1.0]hexene nucleosides: the effect of ring planarity on anti-HIV activity. ChemMedChem 4:1354-63
Marquez, Victor E; Sun, Guangyu; Siddiqui, Maqbool A et al. (2008) What are the consequences of freezing the anomeric effect in nucleosides? Nucleic Acids Symp Ser (Oxf) :543-4
Siddiqui, Maqbool A; Marquez, Victor E (2007) The triphosphate of beta-D-4'-C-ethynyl-2',3'-dideoxycytidine is the preferred enantiomer substrate for HIV reverse transcriptase. Bioorg Med Chem 15:283-7
Boyer, Paul L; Julias, John G; Marquez, Victor E et al. (2005) Fixed conformation nucleoside analogs effectively inhibit excision-proficient HIV-1 reverse transcriptases. J Mol Biol 345:441-50
Siddiqui, Maqbool A; Hughes, Stephen H; Boyer, Paul L et al. (2004) A 4'-C-ethynyl-2',3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosides. J Med Chem 47:5041-8
Choi, Yongseok; Sun, Guangyu; George, Clifford et al. (2003) Synthesis and conformational analysis of a locked analogue of carbovir built on a bicyclo[3.1.0]hex-2-enyl template. Nucleosides Nucleotides Nucleic Acids 22:2077-91
Choi, Yongseok; George, Clifford; Comin, Maria J et al. (2003) A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude. J Med Chem 46:3292-9